Stephens Investment Management Group LLC Grows Stock Holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Stephens Investment Management Group LLC lifted its stake in shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) by 25.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 502,925 shares of the company’s stock after buying an additional 102,600 shares during the quarter. Stephens Investment Management Group LLC’s holdings in iRhythm Technologies were worth $45,349,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. R Squared Ltd bought a new stake in iRhythm Technologies during the 4th quarter valued at $45,000. Quarry LP purchased a new position in iRhythm Technologies during the 3rd quarter valued at about $59,000. Nisa Investment Advisors LLC raised its holdings in shares of iRhythm Technologies by 166.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company’s stock valued at $94,000 after purchasing an additional 648 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of iRhythm Technologies in the 3rd quarter worth approximately $119,000. Finally, KBC Group NV boosted its stake in shares of iRhythm Technologies by 45.1% during the fourth quarter. KBC Group NV now owns 1,319 shares of the company’s stock valued at $119,000 after purchasing an additional 410 shares in the last quarter.

iRhythm Technologies Stock Up 1.3 %

IRTC stock opened at $110.00 on Friday. The company has a quick ratio of 6.12, a current ratio of 6.27 and a debt-to-equity ratio of 9.00. The firm’s fifty day simple moving average is $96.58 and its 200-day simple moving average is $81.89. iRhythm Technologies, Inc. has a 12 month low of $55.92 and a 12 month high of $124.11.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IRTC. Canaccord Genuity Group upped their target price on iRhythm Technologies from $125.00 to $152.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Truist Financial lifted their price objective on shares of iRhythm Technologies from $85.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Wells Fargo & Company reiterated an “equal weight” rating and set a $86.00 price objective on shares of iRhythm Technologies in a report on Tuesday, December 3rd. Oppenheimer boosted their target price on iRhythm Technologies from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, Needham & Company LLC boosted their price target on iRhythm Technologies from $96.00 to $112.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $108.45.

Insider Buying and Selling at iRhythm Technologies

In other iRhythm Technologies news, insider Patrick Michael Murphy sold 2,492 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $85.89, for a total value of $214,037.88. Following the completion of the transaction, the insider now directly owns 35,327 shares of the company’s stock, valued at approximately $3,034,236.03. The trade was a 6.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.68% of the stock is owned by corporate insiders.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.